KOSDAQBiotech & Pharma260660

Korea Arlico Pharm

₩1,758▼ 6.89%2026-11-18 close
Market Cap
₩26.9B
Turnover
₩39,916,023
Volume
20K
Shares out.
15.3M
PER
—
PBR
0.4×
EPS
-₩228
Dividend Yield
4.03%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩75 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrow, but a Profit Turn Is Still Pending

Third-quarter 2026 sales rose to KRW 53.1 billion and the operating loss narrowed to KRW 802 million, yet the net loss attributable to controlling shareholders widened to KRW 1.14 billion.

  1. 1

    Sales reached KRW 201.2 billion in 2025, up 5.7% year on year, and rose for three consecutive years from 2023 to 2025.

  2. 2

    Operating profit of KRW 989 million in 2025 turned the 2024 operating loss of KRW 5.16 billion into a profit, but the 2025 operating margin was only 0.5%.

  3. 3

    Operating losses have continued for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 3.43 billion.

  4. 4

    The debt ratio climbed from 73.4% in 2022 to 119.7% in 2025, with total equity of KRW 78.2 billion and total liabilities of KRW 93.6 billion at end-2025.

  5. 5

    Prescription drugs accounted for 85.5% of 2025 sales, while non-pharmaceutical businesses such as health functional foods and medical devices expanded to 14.5%.

02

Business structure

Korea Arlico Pharm, founded in 1992, is a prescription-drug-centered pharmaceutical company whose core lineup consists of generic drugs for hyperlipidemia, cerebrovascular disease, hypertension and digestive conditions.

Prescription drugs generated KRW 172.0 billion of the KRW 201.2 billion in 2025 sales, or 85.5% of the total. Health functional foods contributed KRW 13.0 billion, or 6.5%, and other businesses recorded KRW 16.2 billion.

The share of sales from businesses outside prescription drugs widened from 3.6% in 2023 to 14.5% in 2025. Key products include the hyperlipidemia treatments Cres, Arva and Pitastin, the cerebrovascular drugs Colliatin and Alcept, and the digestive agent Nexium.

The company said prescription drugs for hyperlipidemia, cerebrovascular disease and hypertension generated sales in the KRW 46 billion range in the first nine months of 2025.

In October 2025 the company launched Aldeuca, a hypertension combination tablet, widening a lineup that had centered on single-ingredient products. Medical devices and women's care products reached KRW 14.1 billion in cumulative sales over the first nine months of 2025, according to the company.

As generic drug prices fall, the company is expanding in-house production of products it previously sourced externally to strengthen cost competitiveness.

Industry observers note that as generic competition intensifies and pricing policy tightens, smaller pharmaceutical companies are broadening into health functional foods and over-the-counter products.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩52.2B₩4,030,3470.0%
2025Q4₩48.3B-₩1.7B−3.5%
2026Q1₩48.3B-₩1.8B−3.6%
2026Q2₩46.9B-₩4.6B−9.8%
2026Q3₩53.1B-₩800M−1.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩167.7B₩9.9B₩8B5.9%9.1%73.4%
2023₩187.2B₩3.1B₩3.1B1.6%3.4%94.8%
2024₩190.4B-₩5.2B-₩5.4B−2.7%−6.7%116.3%
2025₩201.2B₩1B-₩600M0.5%−0.8%119.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual sales rose from KRW 167.7 billion in 2022 to KRW 187.2 billion in 2023 (up 11.6% year on year), KRW 190.4 billion in 2024 (up 1.8%) and KRW 201.2 billion in 2025 (up 5.7%). Sales rose for three consecutive years from 2023 to 2025, and 2025 was the largest year of the 2022 to 2025 period.

Operating profit fell from KRW 9.86 billion in 2022 to KRW 3.07 billion in 2023 (down 68.9%), swung to an operating loss of KRW 5.16 billion in 2024, and returned to a profit of KRW 989 million in 2025.

The operating margin was 5.9% in 2022, 1.6% in 2023, -2.7% in 2024 and 0.5% in 2025, so margins stayed thin even as sales grew.

Net profit attributable to controlling shareholders fell from KRW 8.03 billion in 2022 to KRW 3.06 billion in 2023 (down 61.9%), turned to a net loss of KRW 5.36 billion in 2024, and narrowed to a net loss of KRW 605 million in 2025. The company recorded losses in two consecutive years from 2024 to 2025.

Net profit including non-controlling interests followed the same direction, with net losses of KRW 5.36 billion in 2024 and KRW 605 million in 2025. Operating cash flow moved from negative KRW 8.58 billion in 2024 to positive KRW 9.99 billion in 2025.

Quarterly sales went from KRW 52.2 billion in the third quarter of 2025 to KRW 48.3 billion in the fourth quarter (down 7.4% from the prior quarter), KRW 48.3 billion in the first quarter of 2026 (unchanged), KRW 46.9 billion in the second quarter (down 3.0%) and KRW 53.1 billion in the third quarter (up 13.3% from the prior quarter).

Operating results moved from a small profit of KRW 4.03 million in the third quarter of 2025 to operating losses of KRW 1.69 billion in the fourth quarter of 2025, KRW 1.76 billion in the first quarter of 2026 and KRW 4.57 billion in the second quarter, before narrowing to KRW 802 million in the third quarter of 2026.

The company attributed the second-quarter loss to a provision linked to collin-related charges, and said selling expense improvements helped in the third quarter. Third-quarter results still reflected higher marketing commissions and inventory burdens from a year earlier.

The net loss attributable to controlling shareholders widened to KRW 1.14 billion from KRW 694 million in the prior quarter, so the narrowing operating loss and the widening net loss moved in opposite directions.

05

Industry analysis

The domestic generic drug market is seeing tighter pricing policy and rising competition at the same time. In its third-quarter 2026 results, the company presented expanding in-house products to offset falling generic prices as a medium- to long-term profitability task.

The company lists reductions in the drug pricing reference standard, stricter quality and licensing regulation, changes in the CSO market and higher costs from a weaker won among its main management risks.

In its first-quarter 2026 review, a third-party assessment also cited pricing system changes and higher development costs from exchange-rate increases as factors making the operating environment difficult.

Smaller pharmaceutical companies are widely seen broadening into health functional foods and over-the-counter products, and Korea Arlico's rising share of non-prescription businesses fits that pattern.

In cycle terms, generics are under cumulative price-cut pressure, so changing the cost structure is the key to profitability.

Compared with large listed companies such as Samsung Biologics and Celltrion, which have grown around biologics, Korea Arlico relies more on domestic prescription generics, so sales growth and margin improvement have followed a different pace.

Reimbursement clawback issues tied to collin alfoscerate are linked to government pricing and reimbursement policy, which makes them part of the industry backdrop.

06

Outlook

In its third-quarter 2026 results, the company said it is improving selling and distribution expenses and the distribution structure, managing the share of lower-margin merchandise sales and reshaping the business around in-house products, and it expected visible results soon.

In the third quarter of 2026, sales rose from the prior quarter and the operating loss narrowed, but the net loss attributable to controlling shareholders widened.

The company said in its first-half 2026 results that it would diversify raw material suppliers and expand in-house manufacturing to strengthen cost competitiveness in the second half.

On the product side, the hypertension combination tablet Aldeuca launched in October 2025, and a 2025 announcement said the company was preparing to launch Crevista and Nifedion CR alongside Alcana, which had already launched.

Erisson Pharmaceutical holds the marketing approvals for the latter two, and the company co-markets them. Health functional food sales grew from KRW 13.0 billion in 2025 to KRW 3.9 billion in the first quarter of 2026, or 8.1% of total quarterly sales.

The company said the KRW 10.5 billion fourth convertible bond issued at the end of 2025 would fund its health functional food business and repay debt.

The next checkpoint is the full-year operating margin in the 2026 annual report and the fourth-quarter result it contains, along with whether provisions linked to collin alfoscerate are actually spent.

07

Valuation

PER
—
PBR
0.4×
ROE
-4.5%
EPS
-₩228
BPS
₩4,942
Dividend per share
₩75

Korea Arlico Pharm has recorded net losses attributable to controlling shareholders over the last four quarters, which makes a price-to-earnings comparison impossible to calculate.

On a book-value basis, the stock trades below a price-to-book ratio of 1x, meaning the share price sits below the company's accounting equity value. Market capitalization is also below the total equity reported at end-2025.

The company's cash dividend was approved at the March 2026 annual general meeting, but while quarterly net losses continue, its sustainability depends more on cash flow and financial capacity than on current earnings.

Operating cash flow turned positive in 2025, which is a relevant fact when assessing dividend capacity. On the other hand, the debt ratio rose to 119.7%, so debt burden relative to equity has grown and should be considered alongside book value.

Over several years, the company moved from a loss in 2024 to a profit in 2025, but operating results in 2026 returned to loss, so the direction of earnings recovery is not yet settled.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Three Years of Rising Sales

Sales rose for three consecutive years, from KRW 187.2 billion in 2023 to KRW 190.4 billion in 2024 and KRW 201.2 billion in 2025. Third-quarter 2026 sales of KRW 53.1 billion were up 13.3% from the prior quarter and 1.7% from a year earlier, showing a recovery in quarterly volume. Prescription drugs of KRW 172.0 billion continue to anchor the top line.

Narrowing Operating Loss and Cost Work

The operating loss narrowed to KRW 802 million in the third quarter of 2026 from KRW 4.57 billion in the second quarter.

The company is working on selling expense and distribution improvements and reshaping the business around in-house products, with supplier diversification and expanded manufacturing as stated priorities. A larger share of in-house products could leave room for the operating margin to improve.

Growth Outside Prescription Drugs

Health functional food sales grew from about KRW 200 million in 2023 to KRW 13.0 billion in 2025, and reached KRW 3.9 billion in the first quarter of 2026, or 8.1% of sales. Businesses outside prescription drugs widened to 14.5% of sales, diversifying the revenue base.

09

Bear factors

Four Consecutive Quarters of Operating Losses

Operating losses continued for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026. Over the same period, the net loss attributable to controlling shareholders totaled KRW 3.43 billion.

The third-quarter 2026 net loss of KRW 1.14 billion was larger than the KRW 694 million in the prior quarter, and controlling-shareholder net losses have run for five consecutive quarters since the third quarter of 2025.

Price Cuts and Cost Pressure

Price-reference cuts, tighter quality and licensing rules, changes in the CSO market and a weaker won are all acting at once, according to the risks the company itself lists. With generics making up most sales, slower cost improvement could keep the operating margin at a low level.

Financial Burden and Provision Uncertainty

The debt ratio rose from 73.4% in 2022 to 119.7% in 2025, and total liabilities of KRW 93.6 billion exceed total equity of KRW 78.2 billion.

Of the KRW 10.5 billion convertible bond issued at end-2025, the company planned to use KRW 8.5 billion to repay debt and KRW 2.0 billion as operating funds for the health functional food business. How much of the collin-related provision will ultimately hit reported profit remains uncertain.

10

Risk factors

Pricing and Regulation

The company identifies cuts to the drug pricing reference standard, stricter quality and licensing rules, and changes in the CSO market as its main management risks. A provision for possible reimbursement clawback on collin alfoscerate was reflected in second-quarter 2026 losses.

The company says most of the third-quarter loss came from provisioning and has little actual profit impact. If the provisions lead to actual clawbacks, the burden on profit could grow again.

Financing

The debt ratio rose from 73.4% in 2022 to 119.7% in 2025, and total liabilities stand at KRW 93.6 billion. At end-2025 the company issued a KRW 10.5 billion fourth convertible bond, and the company said part of the proceeds would repay debt.

Operating cash flow turned positive in 2025, but while losses continue, the debt burden needs to be watched alongside it.

Governance

At the annual general meeting in March 2026, a director compensation ceiling was approved with the support of 7.5% of issued shares. Asia Economy reported the outcome as self-approval, while the company said it applied the quorum-easing principle used when electronic voting is introduced.

Because the largest shareholder and his daughter are the only executive directors, the procedure remains a governance risk that affects shareholder trust.

11

What to watch next

  1. End of March 2027 (statutory filing deadline)

    Filing of the 2026 annual report. It will show whether the 0.5% operating margin of 2025 can hold as a profit trend and the scale of fourth-quarter 2026 operating results.

  2. Around March 2027 (annual general meeting)

    Dividend proposal and the approval method and support rate for the director compensation ceiling, to be compared with how the 2026 ceiling was passed.

  3. Around May 15, 2027 (first-quarter 2027 quarterly report deadline)

    Whether first-quarter 2027 operating results turn to a profit and whether additional collin-related provisions are booked.

  4. Timing not yet set (depends on company disclosure)

    Decision on health insurance reimbursement clawback for collin alfoscerate. The scale of the provision and whether it is actually spent will feed into the operating results.

12

Overall view

Korea Arlico Pharm's sales rose in 2025 and operating profit turned positive, but in 2026 quarterly sales recovered and the operating loss narrowed while the net loss attributable to controlling shareholders widened, so the direction of the earnings recovery is not yet settled.

Strengths include three consecutive years of sales growth, a rise in third-quarter 2026 sales from the prior quarter, a narrower operating loss and plans to improve the cost structure around in-house products.

Weaknesses include four consecutive quarters of operating losses, five consecutive quarters of net losses attributable to controlling shareholders, a rising debt ratio, and pricing and provision risks.

With a 2025 operating margin of only 0.5%, the key issue is whether margins improve enough to change the earnings trend. The stock trades below a price-to-book ratio of 1x, so it is low relative to accounting value, but ongoing losses make earnings-based comparison difficult.

The next checkpoints are the full-year operating margin in the 2026 annual report and whether operating results turn to profit in the first-quarter 2027 quarterly report. This report does not present an investment opinion or target price, and its results figures are based on DART periodic report disclosures.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. dailypharm.com
  2. pharmnews.com
  3. vegannews.co.kr
  4. medipana.com
  5. medisobizanews.com
  6. dailypharm.com
  7. dailypharm.com
  8. whosaeng.com
  9. hitnews.co.kr
  10. etoday.co.kr
  11. hankyung.com
  12. news.nate.com
  13. m.news.nate.com
  14. view.asiae.co.kr
  15. wikileaks-kr.org
  16. wikileaks-kr.org
  17. comp.wisereport.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis